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Abstract 
L-Tryptophan, technically pure, is a feed additive produced by fermentation using a genetically 
modified strain of Escherichia coli (E. coli). The Panel on Additives and Products or Substances used in 
Animal Feed (FEEDAP Panel) of the European Food Safety Authority (EFSA), issued an opinion on the 
safety and efficacy of the product, in which it could not conclude on the safety of this additive for 
target animals, consumer, user and the environment, due to the insufficient characterisation of the 
genetic modification. The European Commission asked EFSA to deliver an opinion on the safety of 
L-tryptophan, technically pure, as nutritional additive for all animal species based on additional data 
submitted by the applicant. The new information provided on the genetic modification, including the 
presence/absence of an antibiotic resistance gene in the production strain, is contradictory. 
Consequently, the FEEDAP Panel cannot conclude on the safety of the L-tryptophan produced using 
E. coli CGMCC 3667 for target animals, consumers, users and the environment. The FEEDAP Panel 
reiterates its concern on the use of unprotected tryptophan to ruminants and on the safety of the 
amino acid L-tryptophan for target species when administered simultaneously via water for drinking. 
As the estimated maximum exposure to endotoxins by inhalation is below the provisional occupational 
exposure limit, no risk from the exposure to endotoxins for people handling the additive is expected. 
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Summary 
Following a request from the European Commission (EC), the European Food Safety Authority (EFSA) 
was asked to deliver a scientific opinion on the safety of L-tryptophan, technically pure, produced by 
fermentation using the genetically modified strain Escherichia coli (E. coli) CGMCC 3667 for all animal 
species. 
In 2014, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) of 
the European Food Safety Authority (EFSA) adopted an opinion on the safety and efficacy of L-
tryptophan produced by fermentation using E. coli CGMCC 3667. The FEEDAP Panel could not 
conclude on the safety of that product for target animals, consumer, user and the environment 
because the genetic modification, including the presence/absence of recombinant deoxyribonucleic 
acid (DNA) and of antibiotic resistance genes in the product, was insufficiently characterised.  
The applicant provided additional information in relation to the characterisation of the production 
microorganism, the characterisation of the additive and its stability. The FEEDAP Panel has performed 
the assessment of those new data following an approach in line with the principles laid down in 
Regulation (EC) No 429/2008 and the relevant guidance documents. 
The new information provided on the genetic modification, including the presence/absence of 
antibiotic resistance genes in the production strain, is contradictory. Consequently, the FEEDAP Panel 
could not conclude on the safety of the L-tryptophan produced by fermentation with E. coli CGMCC 
3667 for the target animals, the consumers, the users and the environment. 
The FEEDAP Panel reiterates its concern on the use of unprotected tryptophan to ruminants and on 
the safety of the amino acid L-tryptophan for target species when administered simultaneously via 
water for drinking. 
As the estimated maximum exposure to endotoxins by inhalation is below the provisional occupational 
exposure limit, no risk from the exposure to endotoxins for people handling the additive is expected.  
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1. Introduction  
1.1. Background and Terms of Reference as provided by the requestor 
Regulation (EC) No 1831/2003 establishes rules governing the Community authorisation of additives 
for animal nutrition and, in particular, Article 9 defines the terms of the authorisation by the 
Commission. 
The applicant, GBT Europe GmbH, is seeking a Community authorisation of L-tryptophan, technically 
pure, produced by fermentation with Escherichia coli (E. coli) to be used as a nutritional additive for 
all animal species (Table 1). 
Table 1:  Description of the substances 
Category of additive Nutritional additive 
Functional group of additive Amino acids, their salts and analogues 
Description L-Tryptophan, technically pure, produced by fermentation with 
Escherichia coli 
Target animal category All animal species 
Applicant GBT Europe GmbH 
Type of request New opinion 
 
On 10 April 2014, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP 
Panel) of the European Food Safety Authority (‘Authority’), in its opinion on the safety and efficacy of 
the product could not conclude on the safety of the L-tryptophan produced by fermentation with this 
recombinant strain of E. coli for target animals, consumer, user and the environment. Regardless of 
the assessment of the genetic modification, the FEEDAP Panel had concerns on the use of 
unprotected forms of L-tryptophan in ruminants, and on the safety of the amino acid L-tryptophan for 
target species when administered simultaneously via water for drinking. 
The Commission gave the possibility to the applicant to submit complementary information in order to 
complete the assessment on the safety and to allow a revision of Authority's opinion. 
The Commission has now received new data on the safety of L-tryptophan, technically pure, produced 
by fermentation with E. coli. 
In view of the above, the Commission asks the Authority to deliver a new opinion on the safety of 
L-tryptophan, technically pure, produced by fermentation with E. coli as a nutritional additive for all 
animal species based on the additional data submitted by the applicant. 
1.2. Additional information  
The applicant has provided additional information on the characterisation of the production 
microorganism, the characterisation of the additive and its stability and homogeneity. 
2. Data and Methodologies  
2.1. Data 
The present assessment is based on the data submitted by the applicant in the form of additional 
information1 following a previous application on the same product.2 
2.2. Methodologies 
The approach followed by the FEEDAP Panel to assess the characterisation and safety of L-tryptophan 
produced by E. coli CGMCC 3667 is consistent with the principles laid down in Regulation (EC) No 
                                                          
1
  Dossier reference: FAD-2015-0011. 
2
  Dossier reference: FAD-2010-0290. 
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429/20083 and the relevant guidance documents: Guidance on nutritional additives (EFSA FEEDAP 
Panel, 2012a), Guidance on the risk assessment of genetically modified microorganisms and their 
products intended for food and feed use (EFSA GMO Panel, 2011), Technical guidance: Update of the 
criteria used in the assessment of bacterial resistance to antibiotics of human or veterinary importance 
(EFSA, 2008, revised in 2012b), Technical Guidance: Microbial Studies (EFSA, 2008) and Guidance on 
studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012c). 
3. Assessment 
L-Tryptophan, technically pure, (minimum content of L-tryptophan 98%, ‘as is’ basis) was first 
authorised for use in animal nutrition by Directive 88/485/EEC.4 It is currently included in the 
European Union Register of Feed Additives pursuant to Regulation (EC) No 1831/2003 concerning 
additives in feedingstuffs. 
The current application is for the authorisation of L-tryptophan, technically pure, produced by a 
genetically modified (GM) strain of E. coli (CGMCC 3667), a derivative of E. coli K-12. It is intended to 
be used in all animal species as a nutritional additive in feed and in water for drinking. The 
characterisation of the additive and the description of the genetic modification were assessed in the 
previous opinion (EFSA FEEDAP Panel, 2014). The genetic modification, including the 
presence/absence of production organism and recombinant DNA genes in the product, was 
insufficiently characterised. Therefore, the present opinion focuses on the new data provided by the 
applicant addressing these uncertainties. 
3.1. Characterisation 
This product has been characterised in a previous opinion (EFSA FEEDAP Panel, 2014). Additional data 
have been submitted on the characterisation of the production strain, on the physical properties of the 
additive and its stability and homogeneity in complete feed, and on the manufacturing process. 
3.1.1. Characterisation of the production organism5 
The technical dossier contains information on the susceptibility of the production strain against the list 
of antibiotics proposed for E. coli in the technical guidance on the assessment of bacterial 
susceptibility to antimicrobials of human and veterinary importance (EFSA FEEDAP Panel, 2012).6  
Although the parent strain E. coli K-12 is not included on EFSA qualified presumption of safety (QPS) 
list (EFSA BIOHAZ Panel, 2013), it is not considered a human or animal pathogen, it has a long history 
of apparent safe use in industrial production and is scientifically recognised as a safe bacterial strain 
not producing toxic substances (US Environmental Protection Agency, 1997; Gorbach, 1978). E. coli K-
12 has been used widely as a model organism in research in microbial genetics and physiology, and 
has widespread use in industrial applications. E. coli K-12 is one of the most extensively studied of all 
microorganisms. Its genome sequence was published in 1997 (Blattner et al., 1997) and confirmed 
the absence of toxigenic potential. It does not appear in the most comprehensive review of 
pathogenic E. coli published by Nataro and Kaper (1998). Indeed, strain K-12 is commonly used as a 
‘basemodel’ (safety reference strain) against which the safety of other E. coli strains is assessed, (see 
Kaper et al. (2004)). It can be therefore assumed that there is no antibiotic or enterotoxin production 
from E. coli K-12.  
  
                                                          
3
 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 
1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and 
the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1. 
4 Commission Directive 88/485/EEC of 326 July 1988 amending the Annex to Council Directive 82/471/EEC concerning certain 
products used in animal nutrition. OJ L 239/36, 30.8.1988, p. 4. 
5 This section of the scientific output is temporarily unavailable to the public pending a final decision on the confidentiality 
request submitted by the applicant . A revised version of the opinion will be made available as soon as this decision-making 
process is concluded. 
6 Technical dossier/Supplementary information April 2015/Annex 2.2.5. 
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Characterisation of the genetic modification7  
In the former assessment of the production strain (EFSA FEEDAP Panel, 2014), the genetic 
modification, including the presence/absence of recombinant DNA and of antibiotic resistance genes in 
the product, was insufficiently characterised. 
The new information provided on the genetic modification, including the presence/absence of 
antibiotic resistance genes in the production strain, is contradictory. A gene coding for resistance to an 
antibiotic which is claimed to be carried by the production strain was shown to be present by 
polymerase chain reaction (PCR) but absent by Southern blot analysis.  
Therefore, uncertainty remains about the identity and the genetic elements actually present in the 
production strain. 
3.1.2. Manufacturing process8 
The applicant declared that no antimicrobial compounds (including antibiotics) were used in the 
production process.9 It has been demonstrated that the final product does not contain antimicrobial 
compounds.10 
Neither viable cells of the production strain,11 nor its (as claimed by the applicant) recombinant DNA 
was detected in three batches of the final product.12 However, because of the uncertainties 
concerning the identity and the genetic elements actually present in the production strain, no 
conclusion can be drawn. 
3.1.3. Physical properties 
The applicant submitted data on dusting potential measured in three batches of the final product 
(Stauber–Heubach). The values ranged between 0.12 and 0.14 g/m3.13 
3.1.4. Stability and homogeneity 
In the previous opinion the stability of the additive in complete feed and the capacity of the additive 
to distribute homogeneously in feed were evaluated by measuring total tryptophan (protein-bound 
plus free L-tryptophan) instead of free L-tryptophan. The FEEDAP Panel noted that the results 
obtained might not fully represent the stability of the added free amino acid or its ability to 
homogeneously distribute in compound feedingstuffs. 
A new stability study in complete feed for piglets was provided. L-Tryptophan (three different batches) 
was used to supplement with 0.04% a mash and pelleted complete feed for piglets (three batches; 
total tryptophan content: 0.24%). Samples were collected after mixing and after pelleting at 80ºC. 
The feed was stored in paper bags for 3 months at 5–30ºC and 30–75% relative humidity. No losses 
were detected.14 
Free tryptophan was analysed in 10 subsamples of the above pelleted complete feed for piglets to 
determine the capacity of the additive to homogeneously distribute in feed. The coefficient of variation 
of supplemental tryptophan was 3%.15 
                                                          
7 This section of the scientific output is temporarily unavailable to the public pending a final decision on the confidentiality 
request submitted by the applicant. A revised version of the opinion will be made available as soon as this decision-making 
process is concluded. 
8 This section of the scientific output is temporarily unavailable to the public pending a final decision on the confidentiality 
request submitted by the applicant . A revised version of the opinion will be made available as soon as this decision-making 
process is concluded. 
9 Technical dossier/Supplementary information April 2015/Annexes 2.2.1 and 2.2.2. 
10 Technical dossier/Supplementary information April 2015/Annexes 2.1.9–2.1.12. 
11 Technical dossier/Supplementary information April 2015/Annex 2.2.4 and Supplementary information September 2015/Annex 
II. 
12 Technical dossier/Supplementary information September 2015/Annex III. 
13 Technical dossier/Supplementary information April 2015/Annex 2.1.14. 
14 Technical dossier/Supplementary information April 2015/Annex 2.1.13. 
15 Technical dossier/Supplementary information April 2015/Annex 2.1.13. 
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3.2. Safety16 
In its previous scientific opinion (EFSA FEEDAP Panel, 2014a), in relation to the safety of the genetic 
modification of the production strain, the Panel concluded: ‘…the genetic modification, including the 
presence/absence of recombinant DNA and of antibiotic resistance genes in the product, is 
insufficiently characterised. Consequently, the FEEDAP Panel cannot conclude on the safety of the 
L-tryptophan produced by fermentation with E. coli (CGMCC 3667) for target animals, consumers, 
users and the environment’. 
The new information provided on the genetic modification, including the presence/absence of 
antibiotic resistance genes in the production strain, is contradictory. Based on this lack of consistency, 
the FEEDAP Panel cannot conclude on the safety of the L-tryptophan produced by fermentation with 
E. coli CGMCC 3667, with respect to the genetic modification of the production strain, for target 
animals, consumers, users and the environment. 
In relation to the concerns of the FEEDAP Panel on the use of unprotected forms of L-tryptophan in 
ruminants or on the safety of the amino acid L-tryptophan for target species when administered 
simultaneously via water for drinking (EFSA FEEDAP Panel, 2014), no information has been provided 
that would make the Panel reconsider its opinion.  
The applicant provided new data on the dusting potential of the additive that allows an assessment of 
the potential risk posed by the bacterial endotoxin activity of the final product for the user. The 
production species, Escherichia coli, is a Gram-negative bacterium. Although the K-12 strain and its 
derivatives are safe from the point of view of enterotoxins and other virulence factors (Gorbach, 1978; 
EPA, 1997; Bauer et al., 2007), E. coli K-12 retains lipopolysaccharide in its cell envelope (Luchi and 
Morrison, 2000; Svensson et al., 2005; Gao et al., 2006) which may potentially result in endotoxin 
activity in the final product. The user can suffer from occupational respiratory disease depending on 
the level of endotoxins in the air and dust (Rylander, 1999; Thorn, 2001). The bacterial endotoxin 
activity was analysed in three batches and ranged from 0.06 to 0.14 IU/mg.17 Dusting potential was 
measured in three batches and ranged between 0.12 and 0.14 g/m3. The fraction of particles having a 
diameter below 100 µm was 50% and the fraction below 50 µm was up to 7%. 18 
The scenario used to estimate the exposure of persons handling the additive to endotoxins in the 
dust, based on the EFSA Guidance on user safety (2012b) is described in Appendix A. The health 
based recommended threshold for the quantity of inhaled endotoxins per working day is 900 IU, 
derived from provisional occupational exposure limits given by the Dutch Expert Committee on 
Occupational Safety (DECOS) (Health Council of the Netherlands, 2010) and the UK Health and Safety 
Executive (HSE, 2013). Based upon the calculation of the potential endotoxin content in dust, the 
inhalation exposure could be up to 11 endotoxin IU per eight-hour working day, indicating no risk 
from the exposure to endotoxins for people handling the additive. 
4. Conclusions 
The new information provided on the genetic modification, including the presence/absence of 
antibiotic resistance genes in the production strain is contradictory. Consequently, the FEEDAP Panel 
could not conclude on the safety of the L-tryptophan produced by fermentation with E. coli CGMCC 
3667 for target animals, consumers, users and the environment. 
The FEEDAP Panel reiterates its concern on the use of unprotected tryptophan to ruminants and on 
the safety of the amino acid L-tryptophan for target species when administered simultaneously via 
water for drinking. 
As the estimated maximum exposure to endotoxins by inhalation is below the provisional occupational 
exposure limit, no risk from the exposure to endotoxins for people handling the additive is expected. 
                                                          
16 This section of the scientific output is temporarily unavailable to the public pending a final decision on the confidentiality 
request submitted by the applicant. A revised version of the opinion will be made available as soon as this decision-making 
process is concluded. 
17 Technical dossier FAD-2010-0290/Supplementary information December 2012/Annex 4. 
18 Technical dossier FAD-2010-0290/Section II.1.5/Annex II.1.2. 
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Abbreviations 
CGMCC China general microbiological culture collection centre 
DECOS Dutch Expert Committee on Occupational Safety 
DNA deoxyribonucleic acid  
EC European Commission 
EPA US Environmental Protection Agency  
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed 
GM genetically modified 
GMO EFSA Panel on Genetically Modified Microorganisms 
HBROEL health-based recommended exposure limit 
HSE British Health and Safety Executive 
IU International unit of endotoxin activity. One IU corresponds to one EU. 
LPS lipopolysaccharide 
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies  
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Appendix A – Safety for the user 
The Effects of endotoxin inhalation and the exposure limits have been described in a previous opinion 
(EFSA FEEDAP Panel, 2015). 
Calculation of maximum acceptable levels of exposure from feed additives 
The likely exposure time according to EFSA guidance (EFSA FEEDAP Panel, 2012c) for additives added 
in premixtures assumes a maximum of 40 periods of exposure per day, each comprising 
20 s = 40  20 = 800 s per day. With an uncertainty factor of 2, maximum inhalation exposure would 
occur for 2  800 = 1 600 s = 0.444 h per day. Again, assuming a respiration volume of 1.25 m3/h, 
the inhalation volume providing exposure to potentially endotoxin-containing dust would be 
0.444  1.25 = 0.556 m3 per day. This volume should contain no more than 900 IU endotoxin, so the 
dust formed from the product should contain no more than 900/0.556 = 1 619 IU/m3. 
Calculation of endotoxin content of dust 
Two key measurements are required to evaluate the potential respiratory hazard associated with 
endotoxin content of the product (the dusting potential of the product, expressed in g/m3; the 
endotoxin activity of the dust, determined by the Limulus amoebocyte lysate assay (expressed in 
IU/g)). If data for the dust are not available, the content of endotoxins of the product can be used 
instead. If the content of endotoxins of the relevant additive is a IU/g and the dusting potential is 
b g/m3, then the content of endotoxins of the dust, c IU/m3, is obtained by the simple multiplication 
a  b. This resulting value is further used for calculation of potential inhalatory exposure by users to 
endotoxin from the additive under assessment (Table 2) (EFSA FEEDAP Panel, 2012c). 
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Table 2:  Estimation of user exposure to endotoxins from the additive L-tryptophan produced by 
Escherichia coli CGMCC 3667, including consideration of using filter mask FF P2 or FF P3 as 
preventative measure 
Calculation Identifier Description Amount Source 
 a Endotoxin content (IU/g product) 140 Technical dossier 
 b Dusting potential (g/m3) 0.14 Technical dossier 
a  b c Endotoxin content in the air (IU/m3)  19.6  
 d No of premixture batches made per 
working day 
40 EFSA FEEDAP 
Panel (2012c) 
 e Time of exposure (s) per production of one 
batch 
20 EFSA FEEDAP 
Panel (2012c) 
d  e f Total duration of daily exposure/worker (s) 800  
 g Uncertainty factor 2 EFSA FEEDAP 
Panel (2012c) 
f  g h Refined total duration of daily 
exposure/worker (s)  
1 600  
h/3 600 i Refined total duration of daily exposure (h) 0.44  
 j Inhaled air (m3) per 8-hour working day 10 EFSA FEEDAP 
Panel (2012c) 
j/8  i k Inhaled air during exposure (m3) 0.56  
c  k l Endotoxin (IU) inhaled during exposure per 
8-hour working day 
11  
 m Health-based recommended exposure limit 
of endotoxin (IU/m3) per 8-hours working 
day 
90 Health Council of 
the Netherlands 
(2010)  
m  j n Health-based recommended exposure limit 
of total endotoxin exposure (IU) per 8-hour 
working day 
900  
l/10  Endotoxins inhaled (IU) per 8-hour working 
day reduced by filter mask FF P2 
(reduction factor 10) 
1.1  
l/20  Endotoxins inhaled (IU) per 8-hour working 
day reduced by filter mask FF P3 
(reduction factor 20) 
0.54  
 
